Protagonist Therapeutics, Inc. (PTGX) Bundle
Understanding Protagonist Therapeutics, Inc. (PTGX) Revenue Streams
Understanding Protagonist Therapeutics, Inc.’s Revenue Streams
The revenue streams for Protagonist Therapeutics, Inc. are primarily derived from license and collaboration agreements, particularly with Takeda and JNJ. The significant revenue influx is attributed to the recent collaboration agreements, which have shaped the financial landscape of the company.
Breakdown of Primary Revenue Sources
For the nine months ended September 30, 2024, the total license and collaboration revenue was $263.8 million, a substantial increase from $0 for the same period in 2023. This revenue primarily stemmed from:
- $255.0 million recognized from the Takeda Collaboration Agreement upfront payment.
- $9.7 million allocated to development services provided during the period.
| Revenue Source | Amount (in millions) | Percentage of Total Revenue |
|---|---|---|
| Takeda Collaboration Agreement | $255.0 | 96.6% |
| Development Services | $9.7 | 3.4% |
| Total | $263.8 | 100% |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate is striking, showcasing a growth of 100% from $0 in 2023 to $263.8 million in 2024. This reflects the successful execution of collaboration agreements and the resulting financial benefits.
Contribution of Different Business Segments to Overall Revenue
The primary contributor to the company's revenue in 2024 was the Takeda Collaboration Agreement, which was responsible for 96.6% of the total revenue. The remaining 3.4% came from development services provided under the collaboration agreement.
Analysis of Significant Changes in Revenue Streams
In 2024, the company experienced a significant shift in its revenue model, moving from a reliance on previous funding mechanisms to a model driven primarily by collaboration agreements. The increase in revenue is largely attributed to:
- The one-time, non-refundable upfront payment of $300.0 million received from Takeda in April 2024.
- Recognition of revenue from collaboration agreements that had previously been deferred or unrecognized.
The following table summarizes the revenue changes:
| Period | License and Collaboration Revenue (in millions) | Year-over-Year Change (in millions) | Percentage Change |
|---|---|---|---|
| 2023 | $0.0 | N/A | N/A |
| 2024 | $263.8 | $263.8 | 100% |
A Deep Dive into Protagonist Therapeutics, Inc. (PTGX) Profitability
A Deep Dive into Protagonist Therapeutics, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported a gross profit of $263.8 million on total revenues primarily from collaboration agreements, resulting in a gross profit margin of 100% as there were no cost of goods sold reported during this period.
Operating Profit Margin: Operating income for the same period was $126.1 million, translating to an operating profit margin of approximately 47.8%.
Net Profit Margin: The net income for the nine months ended September 30, 2024, was $143.5 million, leading to a net profit margin of about 54.4%.
Trends in Profitability Over Time
In comparison to the nine months ended September 30, 2023, where the company experienced a net loss of $106.3 million, the transition to a net income of $143.5 million in 2024 marks a significant turnaround.
The operating income also improved dramatically from a loss of $116.7 million in 2023 to a profit of $126.1 million in 2024.
Comparison of Profitability Ratios with Industry Averages
As of 2024, the average net profit margin in the biotechnology sector is typically around 20% to 30%. The company's net profit margin of 54.4% significantly exceeds this benchmark, indicating strong profitability relative to industry peers.
Analysis of Operational Efficiency
The operational efficiency can be reflected through the company's cost management practices. Research and development expenses for the nine months ended September 30, 2024, were $103.2 million, which represents an increase of 13% from $91.3 million in the previous year.
General and administrative expenses also rose to $34.5 million, up from $25.4 million, marking a 36% increase. Despite the increase in expenses, the substantial revenue from collaboration agreements has allowed for a favorable profit margin trend.
| Metric | 2024 (9 months) | 2023 (9 months) | Change |
|---|---|---|---|
| Gross Profit | $263.8 million | $0 | N/A |
| Operating Income | $126.1 million | ($116.7 million) | $242.8 million |
| Net Income | $143.5 million | ($106.3 million) | $249.8 million |
| R&D Expenses | $103.2 million | $91.3 million | $11.9 million |
| G&A Expenses | $34.5 million | $25.4 million | $9.1 million |
Debt vs. Equity: How Protagonist Therapeutics, Inc. (PTGX) Finances Its Growth
Debt vs. Equity: How Protagonist Therapeutics, Inc. Finances Its Growth
As of September 30, 2024, Protagonist Therapeutics, Inc. reported total liabilities of $71.9 million and total stockholders' equity of $531.9 million. The company's accumulated deficit stood at $472.2 million.
Overview of the Company's Debt Levels
Protagonist Therapeutics has not reported any long-term or short-term debt on its balance sheet as of the latest financial statements. This indicates a reliance on equity financing rather than debt financing to support its operations and growth.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Protagonist Therapeutics is effectively 0.00, given the absence of debt. In comparison, the average debt-to-equity ratio for biotechnology firms typically ranges from 0.25 to 0.50, suggesting that Protagonist operates with significantly less financial leverage.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
There have been no recent debt issuances or refinancing activities reported for Protagonist Therapeutics. The company has maintained a clean balance sheet without any debt obligations, which positions it favorably in terms of financial flexibility.
Balancing Between Debt Financing and Equity Funding
Protagonist Therapeutics has primarily financed its operations through equity funding. For instance, in April 2023, the company completed a public offering of 5,000,000 shares at a price of $20.00 per share, raising approximately $107.8 million in net proceeds. Additionally, the company has utilized the 2022 ATM Facility to generate further equity funding, although no shares were sold under this facility during the nine months ended September 30, 2024.
| Financial Metric | Value |
|---|---|
| Total Liabilities | $71.9 million |
| Total Stockholders' Equity | $531.9 million |
| Accumulated Deficit | $472.2 million |
| Debt-to-Equity Ratio | 0.00 |
| Average Debt-to-Equity Ratio (Industry) | 0.25 - 0.50 |
| Recent Public Offering Shares Issued | 5,000,000 |
| Public Offering Price per Share | $20.00 |
| Net Proceeds from Public Offering | $107.8 million |
Assessing Protagonist Therapeutics, Inc. (PTGX) Liquidity
Assessing Protagonist Therapeutics, Inc.'s Liquidity
As of September 30, 2024, the company had $583.3 million in cash, cash equivalents, and marketable securities, an increase from $341.6 million as of December 31, 2023.
Current and Quick Ratios
The current ratio, which measures the company's ability to cover short-term liabilities with short-term assets, is not explicitly mentioned in the available data. However, the liquidity position is supported by the substantial cash balance. The quick ratio, a more stringent measure excluding inventory, also cannot be calculated without specific current liabilities figures.
Analysis of Working Capital Trends
As of September 30, 2024, the company reported an accumulated deficit of $472.2 million. The increase in cash reserves suggests a positive trend in working capital, with a significant influx from collaboration agreements contributing to available liquidity.
Cash Flow Statements Overview
The following table summarizes the cash flows for the nine months ended September 30, 2024, compared to the same period in 2023:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Cash provided by (used in) operating activities | $213,330 | $(87,196) |
| Cash (used in) provided by investing activities | $(290,758) | $22,029 |
| Cash provided by financing activities | $21,822 | $169,950 |
For the nine months ended September 30, 2024, cash provided by operating activities was primarily driven by net income of $143.5 million and stock-based compensation of $28.5 million. In contrast, cash used in investing activities increased significantly due to purchases of marketable securities totaling $507.3 million.
Potential Liquidity Concerns or Strengths
Despite a strong liquidity position, the company has incurred significant cumulative net losses since inception, totaling $472.2 million. The reliance on collaboration agreements for funding is critical, as future capital needs may arise to support ongoing research and development activities. The company anticipates that existing cash reserves will be sufficient for at least the next twelve months.
Is Protagonist Therapeutics, Inc. (PTGX) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the company reported a market capitalization of approximately $1.2 billion.
Price-to-Earnings (P/E) Ratio
Currently, the company's P/E ratio is not applicable as it reported a net income of $143.5 million for the nine months ended September 30, 2024, translating to a diluted net income per share of $2.22.
Price-to-Book (P/B) Ratio
The book value per share is calculated based on stockholders' equity of $531.9 million and shares outstanding of 59.5 million as of September 30, 2024. Thus, the book value per share is approximately $8.93.
The current stock price is around $20.00, yielding a P/B ratio of approximately 2.24.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) is calculated as market capitalization plus total debt minus cash and cash equivalents. With cash and cash equivalents of $583.3 million and total liabilities of $71.9 million, the enterprise value is approximately $1.2 billion + $71.9 million - $583.3 million = $688.6 million.
Assuming EBITDA for the nine months is similar to the income from operations of $126.1 million, the EV/EBITDA ratio is approximately 5.46.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated significantly, starting at approximately $15.00 and reaching a high of $25.00 before stabilizing around $20.00.
Dividend Yield and Payout Ratios
The company does not currently pay a dividend, and therefore the dividend yield is 0%.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a rating of Buy based on recent collaboration agreements and revenue growth, with a target price of approximately $25.00.
| Valuation Metric | Value |
|---|---|
| Market Capitalization | $1.2 billion |
| P/E Ratio | N/A |
| P/B Ratio | 2.24 |
| EV/EBITDA Ratio | 5.46 |
| Stock Price (Current) | $20.00 |
| 12-Month High | $25.00 |
| 12-Month Low | $15.00 |
| Dividend Yield | 0% |
| Analyst Consensus Rating | Buy |
Key Risks Facing Protagonist Therapeutics, Inc. (PTGX)
Key Risks Facing Protagonist Therapeutics, Inc.
The financial health of Protagonist Therapeutics, Inc. is influenced by various internal and external risk factors. These risks can significantly impact its operational performance and market position.
Industry Competition
The biotechnology industry is highly competitive, with numerous firms engaged in similar research and development activities. The company faces competition from established pharmaceutical companies and emerging biotech firms. As of September 30, 2024, the company reported an accumulated deficit of $472.2 million, highlighting the financial pressures associated with competition and the need for continuous innovation to maintain market relevance.
Regulatory Changes
The company is subject to stringent regulatory oversight from agencies such as the FDA. Any changes in regulations or delays in the approval process for product candidates can adversely affect timelines and revenue generation. For instance, the company may need to allocate up to $50 million upon FDA approval of new drug applications.
Market Conditions
Market volatility and economic uncertainty can affect the company's ability to raise capital. The company had $583.3 million in cash, cash equivalents, and marketable securities as of September 30, 2024, which is critical for funding ongoing operations. However, adverse market conditions may limit access to additional funding sources necessary for research and development.
Operational Risks
Operational risks include challenges in clinical trial execution and patient enrollment. The company reported an increase in research and development expenses, totaling $103.2 million for the nine months ended September 30, 2024, a 13% increase from the previous year. These expenses need to be managed effectively to ensure sustainable operations.
Financial Risks
Financial risks stem from the company's ongoing operating losses and the necessity for additional funding. The company anticipates continued losses as it invests in product development. It reported a net income of $143.5 million for the nine months ended September 30, 2024, but this was primarily due to collaboration revenue. Future funding may not be available on favorable terms, impacting growth and operational capabilities.
Mitigation Strategies
The company has several strategies to mitigate these risks:
- Engaging in strategic collaborations to share development costs and risks, as evidenced by the $300 million upfront payment received under the Takeda Collaboration Agreement.
- Maintaining a robust cash position to fund ongoing research and development activities, with a current balance of $583.3 million.
- Implementing effective project management to streamline clinical trials and improve patient recruitment efforts.
Financial Data Summary
| Category | Amount |
|---|---|
| Accumulated Deficit | $472.2 million |
| Cash and Marketable Securities | $583.3 million |
| Research and Development Expenses (2024) | $103.2 million |
| Collaboration Revenue (2024) | $263.8 million |
| Net Income (Loss) (2024) | $143.5 million |
Future Growth Prospects for Protagonist Therapeutics, Inc. (PTGX)
Future Growth Prospects for Protagonist Therapeutics, Inc.
Analysis of Key Growth Drivers
The company has identified several key growth drivers:
- Product Innovations: The development of rusfertide and JNJ-2113 is expected to enhance the product pipeline.
- Market Expansions: Collaborative efforts with Takeda and JNJ aim to penetrate new therapeutic areas.
- Acquisitions: Future acquisitions may bolster the product portfolio and enhance market reach.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, license and collaboration revenue reached $263.8 million, a significant increase from $0 in the same period of 2023. This revenue surge is primarily attributed to the Takeda Collaboration Agreement, including a one-time upfront payment of $300 million.
Operating income for the same period was reported at $126.1 million, compared to a loss of $116.7 million in 2023.
Strategic Initiatives or Partnerships
Strategic collaborations have been pivotal for growth:
- Takeda Collaboration Agreement: This partnership focuses on the co-development and commercialization of rusfertide, with potential milestone payments totaling $115 million upon achievement of specific regulatory and clinical milestones.
- JNJ Collaboration: The collaboration with JNJ has resulted in milestone payments totaling $172.5 million since its inception in 2017.
Competitive Advantages
The company possesses several competitive advantages that position it favorably for growth:
- Strong Cash Position: As of September 30, 2024, the company had $583.3 million in cash, cash equivalents, and marketable securities.
- Experienced Leadership: The management team has extensive experience in drug development and commercialization.
- Innovative Technology Platforms: The proprietary drug discovery platform supports the development of novel therapeutics, enhancing the pipeline's potential.
Financial Summary Table
| Metric | 2024 (9 Months Ended) | 2023 (9 Months Ended) | Change |
|---|---|---|---|
| License and Collaboration Revenue | $263.8 million | $0 | $263.8 million increase |
| Operating Income (Loss) | $126.1 million | ($116.7 million) | $242.8 million increase |
| Net Income (Loss) | $143.5 million | ($106.3 million) | $249.8 million increase |
| Cash, Cash Equivalents, and Marketable Securities | $583.3 million | $341.6 million | $241.7 million increase |
Protagonist Therapeutics, Inc. (PTGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Protagonist Therapeutics, Inc. (PTGX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Protagonist Therapeutics, Inc. (PTGX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Protagonist Therapeutics, Inc. (PTGX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.